Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T4SG
|
|||
| Former ID |
DCL000460
|
|||
| Drug Name |
AZD1981
|
|||
| Synonyms |
AZD1981; 802904-66-1; AZD-1981; UNII-2AD53WQ2CX; AZD 1981; 2AD53WQ2CX; CHEMBL1914489; 2-[4-acetamido-3-(4-chlorophenyl)sulfanyl-2-methylindol-1-yl]acetic acid; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-((4-chlorophenyl)thio)-2-methyl-; 1H-Indole-1-acetic acid, 4-(acetylamino)-3-[(4-chlorophenyl)thio]-2-methyl-; JWYIGNODXSRKGP-UHFFFAOYSA-N; GTPL7680; SCHEMBL1053662; EX-A662; MolPort-035-395-811; HMS3653A06; BCP20957; ZINC73196066; s7263; BDBM50357102; AKOS027263775; SB16902; DB11946; CS-4189; NCGC00386290-04; HY-15950; SC-94603
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H17ClN2O3S
|
|||
| Canonical SMILES |
CC1=C(C2=C(C=CC=C2N1CC(=O)O)NC(=O)C)SC3=CC=C(C=C3)Cl
|
|||
| InChI |
1S/C19H17ClN2O3S/c1-11-19(26-14-8-6-13(20)7-9-14)18-15(21-12(2)23)4-3-5-16(18)22(11)10-17(24)25/h3-9H,10H2,1-2H3,(H,21,23)(H,24,25)
|
|||
| InChIKey |
JWYIGNODXSRKGP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 802904-66-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor 2 (PTGDR2) | Target Info | Antagonist | [3] |
| Reactome | Prostanoid ligand receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7680). | |||
| REF 2 | ClinicalTrials.gov (NCT00766415) 14729-D9831C00002- 1 Month Biopsy Study. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.